Therapeutic Response

FGFR2 rearrangements status confers therapeutic sensitivity to Futibatinib in patients with Cholangiocarcinoma.

Statements

Source and description
Lytgobi (futibatinib) [product information]. EMA. The European Medicines Agency (EMA) has given futibatinib conditional market authorization as a monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor 2 (FGFR2) fusion or rearrangement that have progressed after at least one line of prior systemic therapy.